Pfizer crushed Q2 estimates with $14.7B revenue and $0.78 EPS, signaling a powerful turnaround driven by broad-based growth and operational excellence. A successful cost realignment program drove the ...

BridgeBio Pharma Inc. is challenging Pfizer Inc. and Alnylam Pharmaceuticals, Inc. with a heart medicine that it says has better results at a lower cost. But it claims rivals are using questionable ...

Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...

Pfizer PFE announced a definitive agreement to acquire obesity drug developer, Metsera MTSR, to re-enter the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss ...

Pfizer acquires Metsera for up to $7.3B, aiming to enter the high-growth obesity drug market and diversify its portfolio.